A Simple Key For ABBV-744 BRD4 inhibition in cancer cell lines Unveiled
In Segment C, contributors will obtain ABBV-744 and oral navitoclax. In Phase D, individuals will get ABBV-744 and ruxolitinib. Participants will obtain treatment right until ailment progression or the members are unable to tolerate the study drugs.- "Our study uncovered the critical position on the KLF16/MYC regulatory axis in modulating tumor pro